Serologic study of specimens with borderline FTA-ABS test reactivity. 1977

D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn

The treponemal group-specific absorbed fluorescent antibody test (FTA-ABS) does not yield clearly positive or negative results in all instances. This study was designed to analyze those sera showing borderline reactivity, in order to determine whether additional tests may help to resolve serodiagnostic problem cases. FTA-ABS tests on 23,807 sera submitted to the Wisconsin State Laboratory of Hygiene yielded borderline results with 479 specimens (2%). Patients showing inconclusive FTA-ABS test reactivity were equally distributed among older and younger age groups, and 6% of borderline cases were women. Of all the 479 specimens, only five sera (1%) gave a non-specific hemagglutination with the Treponema pallidum microhemagglutination (MHA-TP) test, with 82.5% of the FTA-ABS test borderline sera yielding negative results with the MHA-TP test. Because recent findings had shown atypical false fluorescence with the FTA-ABS test on sera from patients with antinuclear antibody, the fluorescent antinuclear antibody test (FANA) was also performed on specimens inconclusive with the FTA-ABS test. Only seven sera (1.5%) were reactive by the FANA test, suggesting that antinuclear antibody was not a significant cause of borderline FTA-ABS reactions. The implications of these findings to venereal disease serology laboratory practice are discussed.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006386 Hemagglutination Tests Sensitive tests to measure certain antigens, antibodies, or viruses, using their ability to agglutinate certain erythrocytes. (From Stedman, 26th ed) Hemagglutination Test,Test, Hemagglutination,Tests, Hemagglutination
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
October 1982, MMW, Munchener medizinische Wochenschrift,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
August 1970, The British journal of venereal diseases,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
July 1966, The Journal of the Maine Medical Association,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
April 1976, JAMA,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
October 1971, JAMA,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
August 1970, The British journal of venereal diseases,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
October 1971, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
July 1971, JAMA,
D Baertschy, and R Golubjatnikov, and M Steadman, and S L Inhorn
January 1972, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology,
Copied contents to your clipboard!